[1] MUZAALE A D, MASSIE A B, WANG M C, et al. Risk of end-stage renal disease following live kidney donation [J]. JAMA, 2014, 311(6): 579-86.
[2] ORTIZ A, COVIC A, FLISER D, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure [J]. Lancet, 2014, 383(9931): 1831-43.
[3] LI P K, CHOW K M, VAN DE LUIJTGAARDEN M W, et al. Changes in the worldwide epidemiology of peritoneal dialysis [J]. Nat Rev Nephrol, 2017, 13(2): 90-103.
[4] JAIN A K, BLAKE P, CORDY P, et al. Global trends in rates of peritoneal dialysis [J]. J Am Soc Nephrol, 2012, 23(3): 533-44.
[5] SMIT W, PARIKOVA A, KREDIET R T. Ultrafiltration failure in peritoneal dialysis. Causes and clinical consequences [J]. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2005, 57(3): 165-74.
[6] WILLIAMS J D, CRAIG K J, TOPLEY N, et al. Morphologic Changes in the Peritoneal Membrane of Patients with Renal Disease [J]. Journal of the American Society of Nephrology, 2002, 13(2): 470-9.
[7] ZHOU Q, BAJO M A, DEL PESO G, et al. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients [J]. Kidney Int, 2016, 90(3): 515-24.
[8] PITTENGER M F, MACKAY A M, BECK S C, et al. Multilineage potential of adult human mesenchymal stem cells [J]. Science, 1999, 284(5411): 143-7.
[9] PROCKOP D J, OH J Y. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation [J]. Mol Ther, 2012, 20(1): 14-20.
[10] PARFENOVA H, LEFFLER C W, TCHERANOVA D, et al. Epileptic seizures increase circulating endothelial cells in peripheral blood as early indicators of cerebral vascular damage [J]. Am J Physiol Heart Circ Physiol, 2010, 298(6): H1687-98.
[11] WEI X, YANG X, HAN Z P, et al. Mesenchymal stem cells: a new trend for cell therapy [J]. Acta Pharmacol Sin, 2013, 34(6): 747-54.
[12] KANAZAWA H, FUJIMOTO Y, TERATANI T, et al. Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model [J]. PLoS One, 2011, 6(4): e19195.
[13] NAGAYA N, KANGAWA K, ITOH T, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy [J]. Circulation, 2005, 112(8): 1128-35.
[14] NINICHUK V, GROSS O, SEGERER S, et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice [J]. Kidney Int, 2006, 70(1): 121-9.
[15] SAMSONRAJ R M, RAGHUNATH M, NURCOMBE V, et al. Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine [J]. Stem Cells Transl Med, 2017, 6(12): 2173-85.
[16] ZHAO K, LIU Q. The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation [J]. J Hematol Oncol, 2016, 9(1): 46.
[17] CHU D, DU M, HU X, et al. Paeoniflorin attenuates schistosomiasis japonica-associated liver fibrosis through inhibiting alternative activation of macrophages [J]. Parasitology, 2011, 138(10): 1259-71.
[18] MURPHY B S, BUSH H M, SUNDARESHAN V, et al. Characterization of macrophage activation states in patients with cystic fibrosis [J]. J Cyst Fibros, 2010, 9(5): 314-22.
[19] MURRAY L A, ROSADA R, MOREIRA A P, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages [J]. PLoS One, 2010, 5(3): e9683.
[20] CAO Q, HARRIS D C, WANG Y. Macrophages in kidney injury, inflammation, and fibrosis [J]. Physiology (Bethesda), 2015, 30(3): 183-94.
[21] CAO Q, WANG Y, HARRIS D C. Macrophage heterogeneity, phenotypes, and roles in renal fibrosis [J]. Kidney Int Suppl (2011), 2014, 4(1): 16-9.
[22] CHOI H, LEE R H, BAZHANOV N, et al. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages [J]. Blood, 2011, 118(2): 330-8.
[23] YANG C Y, CHANG P Y, CHEN J Y, et al. Adipose-derived mesenchymal stem cells attenuate dialysis-induced peritoneal fibrosis by modulating macrophage polarization via interleukin-6 [J]. Stem Cell Res Ther, 2021, 12(1): 193.
[24] MIZUNO M, ITO Y, HEPBURN N, et al. Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model [J]. J Immunol, 2009, 183(2): 1403-12.
[25] KIM H, MIZUNO M, FURUHASHI K, et al. Rat adipose tissue-derived stem cells attenuate peritoneal injuries in rat zymosan-induced peritonitis accompanied by complement activation [J]. Cytotherapy, 2014, 16(3): 357-68.
[26] SEKIGUCHI Y, HAMADA C, RO Y, et al. Differentiation of bone marrow-derived cells into regenerated mesothelial cells in peritoneal remodeling using a peritoneal fibrosis mouse model [J]. J Artif Organs, 2012, 15(3): 272-82.
[27] WANG N, LI Q, ZHANG L, et al. Mesenchymal stem cells attenuate peritoneal injury through secretion of TSG-6 [J]. PLoS One, 2012, 7(8): e43768.
[28] AROEIRA L S, AGUILERA A, SANCHEZ-TOMERO J A, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions [J]. J Am Soc Nephrol, 2007, 18(7): 2004-13.
[29] MARGETTS P J, BONNIAUD P, LIU L, et al. Transient overexpression of TGF-beta1 induces epithelial mesenchymal transition in the rodent peritoneum [J]. J Am Soc Nephrol, 2005, 16(2): 425-36.
[30] YANG A H, CHEN J Y, LIN J K. Myofibroblastic conversion of mesothelial cells [J]. Kidney Int, 2003, 63(4): 1530-9.
[31] STRIPPOLI R, MORENO-VICENTE R, BATTISTELLI C, et al. Molecular Mechanisms Underlying Peritoneal EMT and Fibrosis [J]. Stem Cells Int, 2016, 2016(3543678.
[32] CANO A, PéREZ-MORENO M A, RODRIGO I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression [J]. Nat Cell Biol, 2000, 2(2): 76-83.
[33] YANG J, DAI C, LIU Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition [J]. J Am Soc Nephrol, 2005, 16(1): 68-78.
[34] UENO T, NAKASHIMA A, DOI S, et al. Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-β1 signaling [J]. Kidney Int, 2013, 84(2): 297-307.
[35] ZOU X Z, LIU T, GONG Z C, et al. MicroRNAs-mediated epithelial-mesenchymal transition in fibrotic diseases [J]. Eur J Pharmacol, 2017, 796(190-206.
[36] YANAI K, ISHII H, AOMATSU A, et al. MicroRNAs in peritoneal fibrosis: a systematic review [J]. Discov Med, 2018, 26(145): 271-80.
[37] LI D, LU Z, LI X, et al. Human umbilical cord mesenchymal stem cells facilitate the up-regulation of miR-153-3p, whereby attenuating MGO-induced peritoneal fibrosis in rats [J]. J Cell Mol Med, 2018, 22(7): 3452-63.
[38] LIU B, GUAN Q, LI J, et al. Mesenchymal stroma cells in peritoneal dialysis effluents from patients [J]. Hum Cell, 2017, 30(2): 51-9.
[39] BASTUG F, GUNDUZ Z, TULPAR S, et al. Compare the effects of intravenous and intraperitoneal mesenchymal stem cell transplantation on ultrafiltration failure in a rat model of chronic peritoneal dialysis [J]. Ren Fail, 2014, 36(9): 1428-35.
[40] NAGASAKI K, NAKASHIMA A, TAMURA R, et al. Mesenchymal stem cells cultured in serum-free medium ameliorate experimental peritoneal fibrosis [J]. Stem Cell Res Ther, 2021, 12(1): 203.
[41] DYKSTRA J A, FACILE T, PATRICK R J, et al. Concise Review: Fat and Furious: Harnessing the Full Potential of Adipose-Derived Stromal Vascular Fraction [J]. Stem Cells Transl Med, 2017, 6(4): 1096-108.
[42] COSTALONGA E C, FANELLI C, GARNICA M R, et al. Adipose-Derived Mesenchymal Stem Cells Modulate Fibrosis and Inflammation in the Peritoneal Fibrosis Model Developed in Uremic Rats [J]. Stem Cells Int, 2020, 2020(3768718.
[43] DALOUS J, LARGHERO J, BAUD O. Transplantation of umbilical cord-derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives [J]. Pediatr Res, 2012, 71(4 Pt 2): 482-90.
[44] HUANG X Z, WEN D, ZHANG M, et al. Sirt1 activation ameliorates renal fibrosis by inhibiting the TGF-beta/Smad3 pathway [J]. J Cell Biochem, 2014, 115(5): 996-1005.
[45] GUO Y, WANG L, GOU R, et al. SIRT1-modified human umbilical cord mesenchymal stem cells ameliorate experimental peritoneal fibrosis by inhibiting the TGF-β/Smad3 pathway [J]. Stem Cell Res Ther, 2020, 11(1): 362.
[46] DU Y, ZONG M, GUAN Q, et al. Comparison of mesenchymal stromal cells from peritoneal dialysis effluent with those from umbilical cords: characteristics and therapeutic effects on chronic peritoneal dialysis in uremic rats [J]. Stem Cell Research & Therapy, 2021, 12(1):
[47] WANG N, SHAO Y, MEI Y, et al. Novel mechanism for mesenchymal stem cells in attenuating peritoneal adhesion: accumulating in the lung and secreting tumor necrosis factor α-stimulating gene-6 [J]. Stem Cell Res Ther, 2012, 3(6): 51.
[48] ALATAB S, SHEKARCHIAN S, NAJAFI I, et al. Systemic Infusion of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Peritoneal Dialysis Patients: Feasibility and Safety [J]. Cell J, 2019, 20(4): 483-95.
[49] JIANG H Y, WANG J P, BAI Y H, et al. Clinical observation of umbilical cord mesenchymal stem cell transplantation for treating patients receiving peritoneal dialysis [J]. Minerva Urol Nefrol, 2018, 70(1): 95-101.
[50] REN H, SANG Y, ZHANG F, et al. Comparative Analysis of Human Mesenchymal Stem Cells from Umbilical Cord, Dental Pulp, and Menstrual Blood as Sources for Cell Therapy [J]. Stem Cells Int, 2016, 2016(3516574.
[51] CIMINO M, GONCALVES R M, BARRIAS C C, et al. Xeno-Free Strategies for Safe Human Mesenchymal Stem/Stromal Cell Expansion: Supplements and Coatings [J]. Stem Cells Int, 2017, 2017(6597815.
[52] CESARZ Z, TAMAMA K. Spheroid Culture of Mesenchymal Stem Cells [J]. Stem Cells Int, 2016, 2016(9176357.
